Independent educationNo sales. No dosing. Sources on every brief.

Exact claim · Version 1 · Reviewed

“The side effects are just nausea and flushing.”

A verdict on this wording and scope, not a universal grade for Melanotan II.

01 · Verdict

Not established

Nausea is the dominant effect in the trial record, severe in 12.9 per cent of subjects at the higher dose in the 2000 study. But the published case literature also contains rhabdomyolysis and renal impairment requiring intensive care, renal infarction affecting roughly half a kidney, and acute ischaemic priapism that failed drug and irrigation treatment and required surgical decompression, a time-critical emergency carrying permanent erectile-dysfunction risk. These are case reports: they prove occurrence, not frequency. The honest statement is that the frequency of serious harm is unknown because no surveillance system exists, not that serious harm is rare.

Evidence basis
Observational human evidence
Scope
The completeness of the adverse-effect picture. Case reports establish that these events happened after use with temporal association; they cannot establish incidence or causation.
Category
Safety

02 · Primary record

Check the attached evidence

Editorial review
Internal editorial review recorded
Responsible editor
Anthony Treviso · Founder and responsible editor
Clinical-review boundary
Not independently medically reviewed.